Turning a valuable technology invention into a successful product is a lot like solving what public transit experts call the “last mile problem.” No matter how good your network of buses and trains, people won’t ride them if the bus stop... Read more »
If there’s one thing that many cleantech startups have come to realize, it’s the importance of having access to companies with deep pockets. In energy and water, big corporations, or “strategic partners,” can provide the funding and expertise that’s often needed... Read more »
With barely a whisper, Seattle biotech Allozyne has been broken up for parts, with most of its assets sold off earlier this summer to a previous licensing partner, Xconomy has learned.
The buyer was MedImmune, the biotech division of the multinational... Read more »
If the cooler days and earlier sunsets weren’t enough of a clue, the flurry of tech-company product announcements should really seal the deal: time is running out on 2014. And if you’re not careful, it’s easy to wind up with a headful of spin,... Read more »
CyPhy Works has been awarded a contract with the Air Force to build a small drone for search-and-rescue operations, its second military contract.
The Danvers, MA-based company said today that it will design and test the Extreme Access Pocket Flyer, a... Read more »
The smart home is a product category marked by hype and unfulfilled promises. Now, entrepreneurs and investors think improved technology will get consumers to finally bite on home automation.
Earlier this month, Savant Systems said it raised $90 million from private equity... Read more »
A little more than a year ago, Salesforce announced it was paying $2.5 billion to acquire marketing software company ExactTarget. It was the largest in a string of buyouts meant to make Salesforce more competitive in digital marketing, giving it more... Read more »
Tokai Pharmaceuticals may be trying to break into an increasingly crowded field of prostate cancer drugs, but Wall Street investors clearly like its chances to make an impact.
Cambridge, MA-based Tokai priced its IPO at $15 per share, the top... Read more »
Third Rock Ventures started up MyoKardia in 2012 around the idea of making genetically targeted drugs for certain forms of heart disease. Two years and $38 million in venture funding into the effort, French pharmaceutical giant Sanofi is buying into the... Read more »
It wasn’t too long ago that Proteon Therapeutics looked to be a piece of Novartis’ portfolio. That deal flamed out, however, leading the Waltham, MA-based biotech to retrench, find some new investors, and—as the company as just disclosed today—chart a course... Read more »